{"entity":{"id":"shen-lin","kind":"person","name":"Lin Shen","aka":[],"tldr":"Led the CT041 trials that produced the first CAR-T therapy approved for a solid tumour, in gastric cancer.","summary":"Lin Shen is Professor and Director of the Department of Gastrointestinal Oncology at Peking University Cancer Hospital in Beijing. Her group ran the phase 1 and randomised phase 2 trials of satricabtagene autoleucel, the Claudin 18.2 CAR-T cell therapy from CARsgen Therapeutics also known as CT041, which produced the first CAR-T therapy approved for a solid tumour, in gastric cancer. Her publications include the interim phase 1 results of Claudin 18.2-specific CAR T cells in gastrointestinal cancers, which also included pancreatic cancer patients. She leads Chinese gastric cancer immunotherapy and HER2 studies, with interests in CAR-T for solid tumours and immunotherapy.","asOf":"2026-09-08","links":[{"label":"Peking University Cancer Hospital","url":"https://www.bjcancer.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shen%20L%5BAuthor%5D%20Peking%20University%20Cancer%20Hospital%20claudin18.2%20CAR-T"}],"tags":[],"related":[],"cancers":["gastric","pancreatic"],"sections":[],"technologies":["car-t"],"targets":["cldn18-2"],"drugs":["satricabtagene-autoleucel"],"companies":["carsgen"],"institutions":["pku-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor and Director, Department of GI Oncology, Peking University Cancer Hospital","institutionId":"pku-cancer-hospital","specialisms":["Gastric cancer","Claudin 18.2","CAR-T for solid tumours","Immunotherapy"],"profiles":[{"label":"Peking University Cancer Hospital","url":"https://www.bjcancer.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Shen%20L%5BAuthor%5D%20Peking%20University%20Cancer%20Hospital%20claudin18.2%20CAR-T"}],"papers":[{"title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","journal":"Nature Medicine","year":2022,"doi":"10.1038/s41591-022-01800-8"},{"title":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer","journal":"New England Journal of Medicine","year":2025,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BREAKWATER+encorafenib+cetuximab+mFOLFOX6+colorectal"},{"title":"CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma","journal":"The Lancet","year":2021,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CheckMate+649+nivolumab+chemotherapy+gastric+Janjigian+Lancet+2021"}]},"route":"/people/shen-lin/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"kras-wild-type-pdac","kind":"cancer","name":"KRAS wild-type pancreatic ductal adenocarcinoma","route":"/cancers/kras-wild-type-pdac/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/"}],"drug":[{"id":"satricabtagene-autoleucel","kind":"drug","name":"Satricabtagene autoleucel","route":"/drugs/satricabtagene-autoleucel/"}],"company":[{"id":"carsgen","kind":"company","name":"CARsgen Therapeutics","route":"/companies/carsgen/"}],"institution":[{"id":"pku-cancer-hospital","kind":"institution","name":"Peking University Cancer Hospital","route":"/institutions/pku-cancer-hospital/"}],"paper":[{"id":"paper-breakwater-nejm-2025","kind":"paper","name":"BREAKWATER: encorafenib plus cetuximab with chemotherapy as first treatment for BRAF V600E-mutated colorectal cancer","route":"/key-papers/paper-breakwater-nejm-2025/"},{"id":"paper-checkmate-649-lancet-2021","kind":"paper","name":"CheckMate 649: nivolumab plus chemotherapy as first treatment for advanced gastric, gastro-oesophageal junction and oesophageal adenocarcinoma","route":"/key-papers/paper-checkmate-649-lancet-2021/"},{"id":"paper-ct041-st-01-lancet-2025","kind":"paper","name":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","route":"/key-papers/paper-ct041-st-01-lancet-2025/"}],"trial":[{"id":"nct04581473","kind":"trial","name":"CT041-ST-01","route":"/trials/nct04581473/"}]}}